FDA's FY 2009 Budget May Increase

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Earlier this week, House Appropriations Committee Chairman Rep. David Obey (D-WI) introduced the FY 2009 Omnibus Appropriations Act (H.R. 1105).

Washington, DC (Feb. 26)-Earlier this week, House Appropriations Committee Chairman Rep. David Obey (D-WI) introduced the FY 2009 Omnibus Appropriations Act (H.R. 1105). Included in the proposed bill is $2.622 billion for the US Food and Drug Administration, approximately $511 million of which is to be derived from prescription drug user fees.

The Center for Drug Evaluation and Research may receive approximately $777 million for its activities and those of the Office of Regulatory Affairs (ORA), $41 million of which would go to the Office of Generic Drugs. The Center for Biologics Evaluation and Research may receive about $271 million for its activities and those of ORA.

In December 2007, Congress enacted the FY 2008 omnibus appropriations, which gave FDA $1.714 billion, and in June 2008, Congress gave the agency another $150 million as part of the FY 2008 emergency supplemental appropriations bill. FDA can use the $150 million through Sept. 30 of this year, according to the Alliance for a Stronger FDA.

Overall, the proposed nearly $2 billion in direct appropriations for FY 2009, ending Sept. 30, 2009, would be a few million more than FDA’s FY 2008 funding of approximately $1.7 billion. The full proposed appropriations bill is available online here.

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Related Content